Drug intelligence / Profile preview

AXB-10507

Development stage
Preclinical
Lead developer
Alexion Pharmaceuticals
Modality
Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Subcutaneous
01

Overview

AXB-10507 is a rat surrogate bispecific VHH (heavy-chain variable domain) antibody targeting rat properdin (factor P, fP) and serum albumin. Developed by Alexion (AstraZeneca Rare Disease), AXB-10507 is used as a preclinical tool to evaluate the therapeutic potential of properdin inhibition, serving as a surrogate for the clinical-stage humanized bispecific VHH antibody ALXN1820 (tarperprumig). AXB-10507 selectively inhibits alternative pathway (AP) complement activation by preventing C3/C5 convertase formation. In preclinical models of experimental autoimmune vasculitis (EAV), subcutaneous administration of AXB-10507 significantly reduced hematuria and proteinuria, and protected against glomerular and tubular damage.

02

Targets

CFP (Complement factor properdin)

Beyond the preview

Go deeper on AXB-10507.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXB-10507.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call